Related Experiment Video
Updated: Jun 14, 2025
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
822
Tirofiban-induced diffuse alveolar haemorrhage.
Bryan Sebastian1, Vijayan Ganesan2, Placid Sebastian1
1Cardiology, Aster MIMS Hospital, Kannur, Kerala, India.
BMJ Case Reports
|August 29, 2024
Summary
A rare complication of tirofiban, a drug used for heart attacks, is diffuse alveolar hemorrhage (DAH). Promptly stopping the medication and providing supportive care led to the patient's recovery.
Area of Science:
- Cardiology
- Pulmonology
- Pharmacology
Background:
- ST-elevation myocardial infarction (STEMI) is a critical cardiac event requiring urgent intervention.
- Tirofiban is an antiplatelet medication used to manage acute coronary syndromes, particularly those with extensive thrombus.
- Diffuse alveolar hemorrhage (DAH) is a serious, often overlooked, pulmonary complication.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
654
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
654
01:24Disorders of Hemostasis
754
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
754
01:16Clot Retraction and Fibrinolysis
4.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.9K